Dhruv Nandakumar

Mr. Dhruv Nandakumar

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2025 in The Journal of Foot and Ankle Surgery
Verified
Journal Article
Closed access
DNDhruv Nandakumar
Dhruv Nandakumar
BCBenjamin M. Conover
Benjamin M. Conover
MJMatthew J. Johnson
Matthew J. Johnson
KRKatherine M. Raspovic
Katherine M. Raspovic
DWDane K. Wukich
Dane K. Wukich

21 March 2026 in Rheumatology and Therapy
Verified
Journal Article
Open access
PDF file
DNDhruv Nandakumar
Dhruv Nandakumar
ABAbhiram R. Bhashyam
Abhiram R. Bhashyam
MLManuel Lubinus
Manuel Lubinus
LWLynn Wilson
Lynn Wilson
JWJerry Williams
Jerry Williams
SBSalman Bhai
Salman Bhai
Introduction Patients with idiopathic inflammatory myopathies (IIMs) can develop marked muscle weakness, which predisposes them to falls and injuries. We examined the prevalence of falls and associated fractures, assistive device use, and bone-protective therapy use among those reporting a fracture history. This analysis focuses on secondary prevention strategies in a high-risk population. Methods A cross-sectional survey was developed and distributed by Myositis Support and Understanding, a patient-led advocacy organization, to members of its group. Patients aged ≥ 18 years with a diagnosis of an IIM (dermatomyositis, antisynthetase syndrome, polymyositis, inclusion body myositis [IBM], immune-mediated necrotizing myopathy, or overlap myositis [OM]) were eligible to participate. Ordinal logistic regression was utilized to identify variables independently associated with falls. Results Of 470 respondents, 79.8% reported falling once since diagnosis, and 57.0% fell within the past year. Fall-related fractures since diagnosis were reported by 121 participants (25.7%), of whom 61 (50.4%) experienced ≥ 2 fractures and 39 (32.2%) required surgical treatment. Among those with fall-related fractures, nearly half (47.9%) reported not receiving any dietary supplements or pharmacologic therapies (e.g., calcium, vitamin D, or bisphosphonates) to reduce bone loss or prevent future fractures. Use of braces/splints or mobility aids was reported by 18.2% and 77.7% of participants with fall-related fractures, respectively. Regression analyses identified mobility aid usage as being associated with a significantly increased fall risk (odds ratio [OR], 3.1; P < 0.001). Relative to dermatomyositis, fall risk was significantly higher among participants with IBM (OR, 2.5; P = 0.002) and polymyositis (OR, 2.0; P = 0.037) and lower for participants with antisynthetase syndrome (OR, 0.5; P = 0.038). Conclusions All IIMs can lead to marked weakness, with varying individual risks of falls. Multidisciplinary care, with an emphasis on primary and secondary prevention of falls and fractures, is critical to improving outcomes and preserving quality of life in these patient populations.

14 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DNDhruv Nandakumar
Dhruv Nandakumar
MLManuel Lubinus
Manuel Lubinus
WJWoohyoung Jeon
Woohyoung Jeon
Background/Objectives: Inclusion body myositis (IBM) causes progressive, quadriceps-predominant weakness that impairs mobility and increases fall risk, yet outcomes most relevant to independence remain unsynthesized for IBM. This review compiles direct IBM evidence across five domains (A1–A5): natural history, motor performance, falls and balance, sensory/peripheral-nerve function, and interventions. Methods: Eight databases and two trial registers were searched without date or language limits. Eligible studies enrolled adults with IBM based on recognized criteria reporting lower-limb strength or function, gait, transitional tasks, balance, falls, or intervention outcomes; mixed-myopathy cohorts required extractable IBM-specific data. Two reviewers independently screened, extracted, and appraised risk of bias, following PRISMA 2020. Results: Sixty-four studies were included; per-domain totals (A1: 16, A2: 9, A3: 6, A4: 2, and A5: 38) exceed 64 because studies may span domains. Quadriceps strength was the most sensitive progression marker, detected earlier by quantitative testing. Falls were near-universal and insufficiently managed. No drug showed convincing functional benefit in controlled trials, whereas exercise and orthotic/robotic assistance appeared to be safe in small studies. Sensory and peripheral-nerve dysfunction were common, but proprioceptive acuity and postural balance were unmeasured. Conclusions: IBM progression is best measured by quantitative quadriceps strength and function. Intervention evidence derives largely from small, uncontrolled and neutral trials. Primary myopathy is likely the principal driver of decline, but its downstream consequences—for balance, proprioception, and falls—remain underexplored and are the priority for future study.